Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.South Korea's exports increased by 12.4% and imports increased by 11.6% from December 1 to 10. South Korea's chip exports increased by 43% year-on-year from December 1 to 10.Nippon Steel's share price rose by 1.2% shortly after the opening on Wednesday, and it is basically flat at present. In the news, US President Biden plans to formally prevent Nippon Steel from acquiring American steel companies for $14.1 billion. American steel stocks plunged overnight, once falling by 22%, and finally closed down by 9.7%.
ADB lowered the growth forecast of developing economies in the Asia-Pacific region to maintain China's economic growth forecast. On December 11th, the Asian Development Bank issued the Asia Development Outlook 2024 (December Edition). According to the report, the development momentum in the Asia-Pacific region is steady, but as US President-elect Trump is about to take office, changes in his trade, finance and immigration policies may inhibit the development of the Asia-Pacific region and aggravate inflation. ADB lowered its growth forecast for developing economies in the Asia-Pacific region from the previous 5.0% to 4.9% in 2024, and from the previous 4.9% to 4.8% in 2025. China's economic growth is expected to remain at 4.8% and 4.5% in 2024 and 2025 respectively, which is the same as before.US Treasury Department: US Treasury Secretary Yellen expressed appreciation for the close communication between the Ministry of Economic Affairs of Korea and the United States after the recent events in South Korea.CITIC Securities: The supply and demand pattern may meet the turning point, paying attention to the strategic allocation value of the magnesium industry. CITIC Securities Research Report said that magnesium prices have stopped falling and stabilized recently, and magnesium as a strategic attribute of China's superior resources is expected to continue to improve. At present, there is a widespread cost inversion in factories, and the willingness to support the price by cost is enhanced, and the purchasing and storage measures are superimposed. We believe that the magnesium price is expected to open an upward channel. At present, the ratio of magnesium to aluminum is reduced to about 0.9 at the bottom, which is conducive to the accelerated promotion of magnesium alloys, and the downstream fields such as new energy vehicles, low-altitude economy, humanoid robots and solid hydrogen storage have broad prospects.
Xie Yunliang, macro chief analyst of Cinda Securities, said that historically, the establishment of a "moderately loose" policy orientation needs to meet two major conditions, namely, the domestic pressure to stabilize prices is high and the foreign Federal Reserve is in a loose cycle. At present, it is judged that both situations may exist next year.Vanke: It received a loan of 1.05 billion yuan from the Postal Savings Bank. On December 10th, Vanke Enterprise Co., Ltd. (Vanke A, 000002.SZ) issued an announcement on providing guarantee for bank loans. According to the announcement, Vanke recently applied for a loan from Shenzhen Luohu Sub-branch of Postal Savings Bank of China Co., Ltd. (hereinafter referred to as "Postal Savings Bank"), with a total loan principal of RMB 1.05 billion, and subsequent companies will make withdrawals according to business needs. The holding subsidiaries of the Company provide corresponding mortgage and pledge guarantee for the relevant loans respectively, and at the same time, the holding subsidiaries, as co-borrower, undertake repayment obligations together with the Company. After this guarantee, the total external guarantee of the company and its holding subsidiaries will be 118.673 billion yuan, accounting for 4.732% of the company's audited net assets attributable to shareholders of listed companies at the end of 2023.Sagitar Juchuang will raise HK$ 277.5 million by placing shares. According to the announcement of the Hong Kong Stock Exchange, the robotics company Sagitar Juchuang agreed to place 10 million new shares at a price of HK$ 27.75 per share. The matching price is about 8% lower than Tuesday's closing price of HK$ 30.15 per share. The proceeds from the placement of shares will be mainly used for research and development, enhancing business development capabilities in overseas markets and exploring potential strategic partnership or alliance opportunities.
Strategy guide
12-13
Strategy guide 12-13